ANUH PHARMA LIMITED·Healthcare Companies·Pharmaceuticals & Biotechnology Companies

Price

76.03

+0.15%
O:76.4
H:76.98
L:75.8
C:76.03

52W Range

6794.89
+13%/-20%

Market Cap

₹762.00 Cr

Traded: ₹0.20 Cr (0.03%) 0.0x

Free Float: ₹206.43 Cr (0.10% of FF traded)

Volume · 60D trend

26.87 K 0.0x

Delivery: % 0.0x

View Delivery Data

Returns

1W:+0% 1M:-4% 3M:-2% 6M:-8% 12M:-4%

Valuation

P/E17.2
P/B2.2
P/S1.0
EV/EBIT122903721.2

Business Strength

ROE10.7%
ROCE14.9%
OPM8.0%
NPM5.3%

Growth (3Y CAGR)

EPS-13.3%
Sales+14.0%
Profit+3.0%
3Y Return+6.0%

Balance Sheet

Debt/Equity0.0
Debt0 Cr
Pledge0.0%
CWIP/Fixed Asset0.0%

Cash Position

CFO/NP-7.3%
FCF-10.8 Cr
FCF 3Y Avg14.1 Cr
Cash/MCap2.0%

Others

Div Yield1.9%
Div Payout37.0%
Cash Conv. Cycle89 days
Tradeable Free Float27.1%

MTF Exposure Trend

60 sessions · funded amount, % of FF, daily delta

Current
₹ 38.81 L
0.19% FF
60d high
₹ 55.42 L
60d low
₹ 27.09 L
60d mean
₹ 40.50 L
vs mean
▼ 4.17%

Growth Trends

Metric10Y5Y3Y1YTTMTrend
Sales
+9.0%
+12.0%
+14.0%
--
+10.0%
Stable
Profit
+4.0%
+10.0%
+3.0%
--
-4.0%
Decelerating
Return
+5.0%
+2.0%
+6.0%
-12.0%
--
Stable
ROE
+13.0%
+14.0%
+14.0%
--
--
Stable

Quarterly Results

Jun 2026

7 Aug
Rev
194 Cr
----
OPM8.0%
NPM--
PAT
--11 Cr
EPS
--1.1

Mar 2026

PDF
Rev
202 Cr
+2% YoY+3% QoQ
OPM10.0%
NPM5.9%
PAT
-6% YoY12 Cr
EPS
-6% YoY1.2

Dec 2025

PDF
Rev
197 Cr
+24% YoY+6% QoQ
OPM10.0%
NPM6.6%
PAT
+30% YoY13 Cr
EPS
+30% YoY1.3

Sep 2025

PDF
Rev
186 Cr
+12% YoY+0% QoQ
OPM6.0%
NPM4.3%
PAT
-49% YoY8 Cr
EPS
-49% YoY0.8

Jun 2025

PDF
Rev
186 Cr
+35% YoY-6% QoQ
OPM6.0%
NPM4.3%
PAT
-13% YoY8 Cr
EPS
-13% YoY0.8

Mar 2025

PDF
Rev
198 Cr
+21% YoY+24% QoQ
OPM9.0%
NPM6.1%
PAT
-19% YoY12 Cr
EPS
-19% YoY1.2

Dec 2024

PDF
Rev
160 Cr
-7% YoY-4% QoQ
OPM9.0%
NPM6.3%
PAT
-46% YoY10 Cr
EPS
-46% YoY1.0

Sep 2024

PDF
Rev
166 Cr
+11% YoY+20% QoQ
OPM10.0%
NPM9.0%
PAT
+9% YoY15 Cr
EPS
+9% YoY1.5

Jun 2024

PDF
Rev
138 Cr
-15% YoY-16% QoQ
OPM8.0%
NPM7.3%
PAT
-19% YoY10 Cr
EPS
-19% YoY0.9

Mar 2024

PDF
Rev
164 Cr
+4% YoY-5% QoQ
OPM12.0%
NPM9.2%
PAT
+60% YoY15 Cr
EPS
+59% YoY1.5

Dec 2023

PDF
Rev
172 Cr
+24% YoY+15% QoQ
OPM14.0%
NPM11.1%
PAT
+105% YoY19 Cr
EPS
--1.9

Sep 2023

PDF
Rev
150 Cr
+30% YoY-7% QoQ
OPM12.0%
NPM9.3%
PAT
+39% YoY14 Cr
EPS
--1.4

Jun 2023

PDF
Rev
161 Cr
+39% YoY+3% QoQ
OPM9.0%
NPM7.5%
PAT
+60% YoY12 Cr
EPS
--1.2

Mar 2023

PDF
Rev
157 Cr
+22% YoY--
OPM9.0%
NPM6.4%
PAT
+8% YoY10 Cr
EPS
--1.0

Revenue & Margin Trends

Annual

Quarterly

Balance Sheet Health

Leverage

Debt / Equity0.00
Interest Coverage-0.3x
Promoter Pledge0.0%
Borrowings0 Cr

Efficiency

Receivable Days113 days
Inventory Days90 days
Payable Days114 days
Cash Conversion cycle89 days

Cash Position

Operating Cash Flow-3 Cr
Investing Cash Flow18 Cr
Financing Cash Flow-26 Cr
Free Cash Flow-11 Cr

Detailed Financials

Jun 2026PDF ↗
Mar 2026PDF ↗
Dec 2025PDF ↗
Sep 2025PDF ↗
Jun 2025PDF ↗
Mar 2025PDF ↗
Dec 2024PDF ↗
Sep 2024PDF ↗
Jun 2024PDF ↗
Mar 2024PDF ↗
Dec 2023PDF ↗
Sep 2023PDF ↗
Jun 2023PDF ↗
Mar 2023PDF ↗
Sales194202197186186198160166138164172150161157
Expenses178182178174176179145149127145148132148143
Operating Profit1620191210191517111924181414
OPM %8.0%10.0%10.0%6.0%6.0%9.0%9.0%10.0%8.0%12.0%14.0%12.0%9.0%9.0%
Other Income3-1213113434231
Interest00000000000000
Depreciation23333322222222
Profit Before Tax1716181011171318122025181513
Tax %32.0%25.0%25.0%23.0%24.0%28.0%22.0%17.0%22.0%22.0%24.0%23.0%24.0%25.0%
Net Profit11121388121015101519141210
Exceptional Items----------------------------
EPS (Rs)1.11.21.30.80.81.21.01.50.91.51.91.41.21.0
Sales Growth (YoY)--2.0%23.6%12.0%35.2%20.9%-7.3%11.0%-14.6%4.2%24.1%29.9%38.8%22.0%
Sales Growth (QoQ)--2.5%5.9%0.0%-6.1%23.8%-3.6%20.3%-15.8%-4.7%14.7%-6.8%2.5%--
OP Growth (YoY)60.0%5.3%26.7%-29.4%-9.1%0.0%-37.5%-5.6%-21.4%35.7%--------
OP Growth (QoQ)-20.0%5.3%58.3%20.0%-47.4%26.7%-11.8%54.5%-42.1%-20.8%33.3%28.6%0.0%--
Profit Growth (YoY)---6.3%30.1%-49.4%-12.7%-18.9%-45.9%8.8%-19.1%59.7%105.3%39.4%60.1%7.7%
EPS Growth (YoY)---5.7%30.1%-49.3%-12.6%-18.9%-46.1%8.7%-18.8%59.4%--------
EPS Growth (QoQ)---12.7%76.3%-8.4%-33.1%20.4%-31.3%57.9%-37.9%-19.9%38.4%17.9%21.9%--
OP Margin--9.9%9.6%6.5%5.4%9.6%9.4%10.2%8.0%11.6%13.9%12.0%8.7%8.9%
Net Margin--5.9%6.6%4.3%4.3%6.1%6.3%9.0%7.3%9.2%11.1%9.3%7.5%6.4%
Material Cost %--75.0%77.0%78.0%82.0%75.0%76.0%75.0%76.0%74.0%73.0%74.0%80.0%78.0%
Employee Cost %--3.0%4.0%4.0%3.0%3.0%3.0%3.0%4.0%3.0%3.0%3.0%3.0%3.0%
P/S0.981.03------------------------
P/E17.2419.35------------------------
P/B2.162.26------------------------

Shareholding Pattern

Shareholders:27.5K (+37.6%)
Current MixJun 2026

Exchange Filings

50
Company Update19 Aug 2026

Investor Presentation for Q1 FY 2026-27

Company Update14 Aug 2026

Disclosure under Regulation 30 of SEBI (LODR), 2015 regarding Change in Management.

Company Update14 Aug 2026

Disclosure of Announcement under Regulation 30 of SEBI (LODR), 2015

AGM/EGM14 Aug 2026

Submission of Scrutinizer Report and Voting Results for the 66th Annual General Meeting of the Company

AGM/EGM12 Aug 2026

Outcome of the 66th Annual General Meeting of Anuh Pharma Limited held on Wednesday, 12th August, 2026

Company Update09 Aug 2026

Newspaper Publication of the Unaudited financial results for the Quarter ended 30th June, 2026, published in the Financial Express in English Language and Mumbai Lakshdeep in Marathi Language ....

Result07 Aug 2026

Unaudited Financial Results for the Quarter ended 30th June, 2026.

Company Update07 Aug 2026

Request received for Withdrawal of application for reclassification of shareholding from "Promoter & Promoter Group'' to ''Public Category''.

Company Update07 Aug 2026

Adoption of Revised Policy of Related Party Transactions.

Board Meeting07 Aug 2026

To consider and approve the Unaudited Financial results along with the Limited Review Report for the quarter ended 30th June, 2026, Request received for withdrawal of application for reclassification ....

Company Update18 Jul 2026

Pursuant to Regulation 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 that a meeting of the Shareholders of the Company will be held on Wednesday, 12th August, ....

Company Update18 Jul 2026

This is to inform to the stock exchange regarding dispatch of physical communication to shareholders who have not registered their email address.

Others18 Jul 2026

Pursuant to the provisions of Regulation 34(1) of the SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015 please find enclosed herewith the copy of the Annual Report ....

AGM/EGM18 Jul 2026

In terms of the provisions of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find attached herewith Notice of the 66th Annual General Meeting of the ....

Company Update14 Jul 2026

Compliance Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026 received from Bigshare Services Private ....

Insider Trading / SAST26 Jun 2026

Intimation regarding the closure of Trading Window for dealing in Securities of the Company shall remain closed from Wednesday, 01st July, 2026 till the expiry of 48 hours after the declaration ....

Company Update20 Jun 2026

Clarification for Newspaper Publication made on 19th June, 2026

Company Update19 Jun 2026

Disclosure under Regulation 30 of the SEBI LODR regarding receipt of Demand Order under Section 156 and Penalty Order under Section 270 of the Income Tax Act, 1961.

Company Update19 Jun 2026

Newspaper Publication for transfer of equity shares of the Company for which Dividend has not been claimed by shareholders for seven consecutive years or more to Investor Education and ....

Company Update29 May 2026

Submission of Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2026.

Company Update28 May 2026

Investor Presentation for Q4 FY 2025-26

Company Update25 May 2026

Intimation for filing of the application for reclassification of shareholders from Promoter Group to Public Category

Company Update22 May 2026

Intimation for the Resolution for reclassification of shareholders from Promoter group to Public category

Company Update22 May 2026

Newspaper Publication of the Audited financial results for the Quarter and Year ended 31st March, 2026, published in the Financial Express in English Language and Mumbai Lakshdeep in Marathi ....

Company Update20 May 2026

Adoption for policy for implementation of NFRA circular

Company Update20 May 2026

Appointment of Scrutinizer for the 66th Annual General Meeting.

Company Update20 May 2026

66th Annual General Meeting will be held on Wednesday, 12th August, 2026 through Video Conferencing and other audio visual means.

Company Update20 May 2026

Adoption of Memorandum of Association (MOA) and Articles of Association (AOA) as per Companies Act, 2013.

Company Update20 May 2026

Granting Authorization to Key Managerial Personnel for Determination of Materiality of Events.

Company Update20 May 2026

Intimation for re-classification of shareholders from Promoter group to public category

Company Update20 May 2026

Re-appointment of Cost Auditor

Company Update20 May 2026

Appointment of Mr. P.N. Rao as General Manager - Quality.

Company Update20 May 2026

Appointment of Internal Auditor.

Company Update20 May 2026

Intimation for Re-appointment of Directors retiring by rotation.

Corp. Action20 May 2026

The record date for dividend is fixed and is enclosed herewith

Corp. Action20 May 2026

Final Dividend of Rs. 1.50 (30%) per equity shares of Face Value of Rs. 5 each for the Financial year ended 31/03/2026

Result20 May 2026

Financial Results for the Financial Year ended 31/03/2026

Board Meeting20 May 2026

Consider and approve the Audited Financial Results for the Financial Year ending 31st March, 2026, and recommendation of Final Dividend for the Financial Year 2025-26, subject to the approval ....

Company Update19 May 2026

Intimation for requests received from Persons belonging to Promoter Group seeking reclassification from Promoter Group to Public.

Board Meeting15 May 2026

Anuh Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 ,inter alia, to consider and approve Audited Financial Results For The ....

Company Update04 May 2026

Approval from World Health Organization (WHO) Prequalification (WHO PQ) for Amodiaquine Hydrochloride USP

Others30 Apr 2026

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Company Update28 Apr 2026

Newspaper Publication for Second 100 Days Campaign - "Saksham Niveshak."

Company Update17 Apr 2026

Newspaper Publication regarding notice to shareholders for Special Window for transfer and dematerialisation (demat) of physical shares in reference to SEBI Circular dated January 30, 2026

Company Update07 Apr 2026

Compliance Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2026 received from Bigshare Services Private ....

Insider Trading / SAST27 Mar 2026

Intimation regarding the closure of Trading Window for dealing in Securities of the Company shall remain closed from Wednesday, 01st April, 2026 till the expiry of 48 hours after the declaration ....

Company Update06 Mar 2026

Completion of European Directorate for the Quality of Medicines & Healthcare (EDQM) Audit and our facilities were found compliant under the Audit

Company Update18 Feb 2026

Newspaper Publication regarding notice to shareholders for Special Window for transfer and dematerialisation (demat) of physical shares in reference to SEBI Circular dated January 30, 2026

Company Update13 Feb 2026

Investor Presentation for Q3 FY 2025-26

Company Update08 Feb 2026

Newspaper publication of the Un-Audited financial results for the Quarter ended 31st December, 2025, published in the Financial Express in English Language and Mumbai Lakshdeep in Marathi ....

Annual Reports

16

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

Credit Ratings

6
icraRating update
15 Sept 2025Report
icraRating update
03 Jan 2025Report
icraRating update
28 Dec 2023Report
icraRating update
20 Oct 2022Report
icraRating update
19 Aug 2021Report
icraRating update
29 Oct 2020Report

Concalls

27

Feb 2026

28 Feb 2026

Nov 2025

30 Nov 2025

Aug 2025

31 Aug 2025

May 2025

31 May 2025

Nov 2024

30 Nov 2024

Feb 2024

29 Feb 2024

Aug 2023

31 Aug 2023

Jun 2023

30 Jun 2023

Feb 2023

28 Feb 2023

Aug 2022

31 Aug 2022

May 2022

31 May 2022

Feb 2022

28 Feb 2022

Feb 2022

28 Feb 2022

Nov 2021

30 Nov 2021

Aug 2021

31 Aug 2021

May 2021

31 May 2021

Feb 2021

28 Feb 2021

Feb 2021

28 Feb 2021

Nov 2020

30 Nov 2020

Aug 2020

31 Aug 2020

Jun 2020

30 Jun 2020

Aug 2019

31 Aug 2019

Dec 2017

31 Dec 2017

Feb 2016

29 Feb 2016

Dec 2015

31 Dec 2015

Sep 2015

30 Sept 2015

Aug 2015

31 Aug 2015

Held by ETFs

1 ETFs hold ANUHPHR · sorted by weight

#ETFWeight %
1

MOHEALTH

MOTILALAMC - MOHEALTH

0.01%

Held by Mutual Funds

1 schemes hold ANUHPHR · sorted by weight

#SchemeWeight %
1

Bandhan BSE Healthcare Index Fund

Bandhan Mutual Fund

0.01%